Vaccines & Disease · Meningococcal

Meningococcal Disease & Vaccine Information

Below are brief introductions to meningococcal disease and the meningococcal vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.

The Disease

Meningococcal: The Disease

Meningococcal disease is a bacterial infection caused by the bacteria Neisseria meningitidis (N. meningitidis).1 There are thirteen identified types (serogroups) of N. meningitidis or meningococci,2 with six causing epidemics resulting in invasive meningococcal disease. Meningitis is the most common form of invasive meningococcal disease, accounting for about 75 percent of all cases.

Symptoms of meningitis usually appear between three and seven days after exposure to the meningococcal bacteria. At first, symptoms may appear mild and similar to cold or flu symptoms, such as headache, fever, aches, and pains. As the illness progresses, additional symptoms may arise, including skin rash, severe headache, stiff neck, nausea, vomiting, inability to look at bright lights, mental confusion and irritability, extreme fatigue/sleepiness, convulsions, and unconsciousness. In babies, symptoms may include a high-pitched moaning cry, difficulty or refusal to feed, and bulging of the fontanel (the soft area on the top of the head).34

The Vaccine

Meningococcal Vaccine

There are currently seven FDA licensed meningococcal vaccines in the U.S. However, two vaccines, Menactra and Menomune, are no longer produced. 567 In total, these vaccines target five of the 13 meningococcal serotypes. Menveo, MenQuadfi, and PENBRAYA are conjugate vaccines that target serogroups A, C, Y and W-135.8 BEXSERO and TRUMENBA are recombinant vaccines that target serogroup B.

The CDC recommends that children 11 to 12 years of age receive the first dose of ACWY meningococcal vaccine conjugate, and a booster dose at age 16. For individuals at age 16 or older, vaccines for all currently available serogroups (A, C, W, Y and B) are recommended by the CDC. The CDC also recommends that high risk children between 2 months and 10 years and high-risk adults be vaccinated with meningococcal conjugate vaccine.

Quick Facts

Meningococcal at a glance

Meningococcal Quick Facts

  1. Meningococcal disease is a serious and potentially life-threatening infection caused by the bacteria Neisseria meningitides. Most frequently, the illness can result in inflammation of the meninges of the brain (meningitis) and a serious bloodstream infection (septicemia/meningococcemia). Invasive meningococcal disease can also present as arthritis and pneumonia.9
  2. Meningococcal disease is not easily spread and requires one to be susceptible to the infection and to have regular close contact with a person who is colonizing the bacteria.10 Between 10-20 percent of individuals are asymptomatic carriers and colonize the bacteria that causes meningococcal disease in the back of their throats.11 Natural community immunity contributes significantly to low disease incidence. Research shows that about 20 to 40 percent of Americans are asymptomatically colonizing meningococcal organisms in their nasal passages and throats.121314 This colonization boosts an individual’s innate immunity to invasive meningococcal infection throughout life.15 The CDC has recognized high levels of innate community immunity and noted that the majority of Americans will experience asymptomatic infection as children or young adults without complications and develop protective bactericidal antibodies against meningococcal disease.1617
  3. Meningococcal rates are low in the U.S. and have steadily declined since the 1990’s. In 2020, there were approximately 235 cases in the U.S. Of these cases 26 percent were unknown and ungroupable serotypes with 20 percent occurring in children too young to be vaccinated. For 2020, 23 death were reported, or less than ten percent of cases.18 Individuals most at risk for contracting meningococcal disease are infants, adolescents, young adults and seniors.19

Meningococcal Vaccine Quick Facts

  1. The CDC states that individuals receiving meningococcal vaccines may experience mild side effects such as pain or redness at the injection site, headache, fatigue, muscle and joint pain, fever, chills, nausea, and diarrhea. Additionally, the CDC warns that persons receiving any vaccine may collapse (faint), experience a severe allergic reaction, and even serious injury and death.2021 Serious adverse events associated with meningococcal vaccines include anaphylaxis, wheezing, upper airway swelling, difficulty breathing, hypotension, itching, hives, lymph node swelling, Guillain-Barre syndrome, convulsions, facial palsy, vasovagal syncope, paresthesia, transverse myelitis, acute disseminated encephalomyelitis, extensive swelling of the injected limb and injection site. 22232425
  2. Meningococcal B vaccines have not been given a routine recommendation by the CDC due to several factors. These factors included the high number of vaccinations that would be required to prevent a single case of the disease, low rates of disease, cost of the vaccine, lack of efficacy and safety data, and the possibility of serious adverse vaccine reactions exceeding the number of cases prevented.26
  3. In 2020, 85.7 percent of college students (18-24 years) and 69.2 percent of persons not attending college (18-24 years) had received at least one dose of MenACWY vaccine. For this same age group and college status, 14.3 percent of college students and 18.2 percent of persons not attending college had received at least one dose of MenB vaccine.27
References
  1. 1Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Meningococcal Disease. Centers for Disease Control (CDC) Aug. 18, 2021.
  2. 2Aquino Gondim FDA. Meningococcal Meningitis. Medscape Jul. 16, 2018.
  3. 3Stuart A. Meningitis Symptoms Warning Signs. WebMD Aug. 7, 2023.
  4. 4US Centers for Disease Control and Prevention. Meningococcal Disease. Feb. 28, 2023.
  5. 5US Food and Drug Administration. Vaccines Licensed for Use in the United States. Oct. 20, 2023.
  6. 6CDPH. VFC Program Update. July 2022.
  7. 7US Food and Drug Administration. Vaccines Licensed for Use in the United States. Oct. 20, 2023.
  8. 8US Food and Drug Administration. Vaccines Licensed for Use in the United States. Oct. 20, 2023.
  9. 9Communication and Education Branch, National Center for Immunization and Respiratory Diseases (NCIRD) and the Centers for Disease Control (CDC). Meningococcal Disease. Centers for Disease Control (CDC) Aug. 18, 2021.
  10. 10US Centers for Disease Control and Prevention. Causes and Spread to Others. Feb. 7, 2022.
  11. 11The College of Physicians of Philadelphia. Bacterial Meningitis (Meningococcal Disease). Jan. 25, 2018.
  12. 12US Food and Drug Administration. Vaccines Licensed for Use in the United States. Oct. 20, 2023.
  13. 13Tan L KK, Cadone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. NEJM April 22, 2010; 362(16): 1511-1520.
  14. 14Manchanda V. Meningococcal Disease: History, Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Antiomicrobial Susceptibility and Prevention. Indian Journal of Medical Microbiology 2006; 24(1): 7-19.
  15. 15FDA. Use of Serum Bactericidal Antibody As an Immunological Correlate for Demonstration of Effectiveness of Meningococcal Conjugate Vaccines (Serogroup A, C, Y, W-135) Administered to Children Less than 2 Years of Age. Apr. 6, 2011.
  16. 16McNamara LA, Blain A. Chapter 8: Meningococcal Disease. Jan 5, 2022.
  17. 17FDA. Use of Serum Bactericidal Antibody As an Immunological Correlate for Demonstration of Effectiveness of Meningococcal Conjugate Vaccines (Serogroup A, C, Y, W-135) Administered to Children Less than 2 Years of Age. Apr. 6, 2011.
  18. 18US Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance report, 2020. Oct. 29, 2023.
  19. 19US Centers for Disease Control and Prevention. Risk Factors. May 1, 2023.
  20. 20US Centers for Disease Control and Prevention. Meningococcal ACWY VIS. Aug. 6, 2021.
  21. 21US Centers for Disease Control and Prevention. Meningococcal B VIS. Aug. 6, 2021.
  22. 22Sanofi Pasteur Inc. Package Insert – Menactra. U.S. Food and Drug Administration Nov. 19, 2019.
  23. 23GlaxoSmithKline Biologicals SA. Package Insert – MENVEO. U.S. Food and Drug Administration Oct. 17, 2022.
  24. 24Wyeth Pharmaceuticals, Inc. Package Insert – Trumemba. U.S. Food and Drug Administration Nov. 23, 2021.
  25. 25GlaxoSmithKline. Package Insert – Bexsero. U.S. Food and Drug Administration Apr. 26, 2023.
  26. 26MacNeil JR. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Oct. 23, 2015; 64(41):1171-6.
  27. 27US Centers for Disease Control and Prevention. Enhanced Meningococcal Disease Surveillance Report, 2020. Oct. 29, 2023.
Select disease / vaccine